Your browser doesn't support javascript.
loading
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges, Laurence; Powles, Tom; Staehler, Michael; Bensalah, Karim; Giles, Rachel H; Hora, Milan; Kuczyk, Markus A; Lam, Thomas B; Ljungberg, Börje; Marconi, Lorenzo; Merseburger, Axel S; Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed; Fernández-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana; Bex, Axel.
Afiliación
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Powles T; The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Staehler M; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Bensalah K; Department of Urology, University of Rennes, Rennes, France.
  • Giles RH; Patient Advocate, International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Hora M; Department of Urology, University Hospital Plzen, Plzen, Czech Republic; Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
  • Kuczyk MA; Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
  • Lam TB; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • Ljungberg B; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
  • Marconi L; Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
  • Merseburger AS; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Volpe A; Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
  • Abu-Ghanem Y; Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
  • Dabestani S; Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.
  • Fernández-Pello S; Department of Urology, Cabueñes Hospital, Gijón, Spain.
  • Hofmann F; Department of Urology, Sunderby Hospital, Sunderby, Sweden.
  • Kuusk T; Department of Urology, Royal Free Hospital, Pond Street, London, UK.
  • Tahbaz R; Department of Urology, Elbe Kliniken Stade, Stade, Germany.
  • Bex A; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK. Electronic address: a.bex@nki
Eur Urol ; 76(2): 151-156, 2019 Aug.
Article en En | MEDLINE | ID: mdl-31151678
ABSTRACT
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT

SUMMARY:

Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renales Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Urol Año: 2019 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renales Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Urol Año: 2019 Tipo del documento: Article País de afiliación: Francia